Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments MarketBeat · Oct 15, 2025
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases. Benzinga · Oct 9, 2025
Best Biotech Stocks to Buy in 2025 Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. MarketBeat · May 13, 2025
3 Mid-Caps Worth Watching Closely in March Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation. MarketBeat · Feb 28, 2025
Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma Akero Therapeutics Inc (NASDAQ:AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE:PFE) at $9.90 per share. The company also announced a term loan facility providing Akero with access to up to $100 million from Hercules Capital Inc (NYSE:HTGC), of which $10 million will be drawn at transaction close. Together with existing cash, proceeds will support… Benzinga · Jun 16, 2022